Merck (MRK) has signed a multi-target discovery collaboration and license agreement with Protillion Biosciences, Protillion said Tuesday.
Under the terms of the agreement, Protillion said it will receive an undisclosed upfront payment, with the potential for up to $510 million upon meeting research, development, and commercial milestone payments for developing multiple therapies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.